-
A study of children with perinatally acquired hepatitis C infection followed for an average of 4.8 years showed persistent HCV infection in 81%, with liver disease that was mild. HCV genotype 3 was associated with a higher rate of loss of HCV RNA and normalization of ALT by 30 months of age.
-
The yeast Candida versatilis was isolated from 10 blood cultures from neonates drawn over a period of 10 days.
-
Prophylactic administration of immunoglobin failed to demonstrate any benefit among recipients of an allogeneic hematopoietic stem cell transplant from HLA-identical sibling donors.
-
Drug discovery activities have yielded agents effective against a novel target in staphylococci.
-
The rapid immunochromatographic urine test Binax NOW was found to be a valuable, sensitive, and rapid test for diagnosing pneumococcal pneumonia even after antibiotic therapy had been started.
-
Pyrazinamide was the most frequent cause of drug-related adverse events, especially hepatitis, among patients with tuberculosis receiving first-line drugs.
-
The Platelia Aspergillus EIA for detecting Aspergillus galactomannan in blood has been recently approved by the Food and Drug Administration for use in the United States.
-
-
The Women's Health Initiative (WHI) was halted 1 year ago, but fallout
from this landmark study continues. The study was designed to identify
the risks or benefits of estrogen plus progesterone vs placebo in
healthy postmenopausal women.
-
The FDA has approved the first nasally administered flu vaccine. This cold-adapted, temperature sensitive, attenuated, trivalent vaccine is manufactured by MedImmune Vaccine, Inc. and marketed by MedImmune and Wyeth under the name FluMist. The nasal flu vaccine should be available this fall.